首页 > 最新文献

World Journal of Gastroenterology最新文献

英文 中文
Gastric metastasis of small cell lung carcinoma: Three case reports and review of literature. 小细胞肺癌的胃转移:三份病例报告和文献综述。
IF 4.3 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-21 DOI: 10.3748/wjg.v30.i31.3717
Shan Yang, Qing-Yun He, Qing-Jing Zhao, Han-Tao Yang, Zheng-Yi Yang, Wen-Yi Che, Hua-Mei Li, Hui-Chao Wu

Background: Small cell lung carcinoma (SCLC) is highly susceptible to metastasis in the early stages of the disease. However, the stomach is an uncommon site of metastasis in SCLC, and only a few cases of this type of metastasis have been reported. Therefore, SCLC gastric metastases have not been systematically characterized and are easily missed and misdiagnosed.

Case summary: We report three cases of gastric metastasis from SCLC in this article. The first patient presented primarily with cough, hemoptysis, and epigastric fullness. The other two patients presented primarily with abdominal discomfort, epigastric distension, and pain. All patients underwent gastroscopy and imaging examinations. Meanwhile, the immunohistochemical results of the lesions in three patients were suggestive of small cell carcinoma. Finally, the three patients were diagnosed with gastric metastasis of SCLC through a comprehensive analysis. The three patients did not receive appropriate treatment and died within a short time.

Conclusion: Here, we focused on summarizing the characteristics of gastric metastasis of SCLC to enhance clinicians' understanding of this disease.

背景:小细胞肺癌(SCLC小细胞肺癌(SCLC)在疾病早期极易发生转移。然而,胃是 SCLC 不常见的转移部位,目前仅有少数此类转移病例的报道。因此,SCLC 胃转移尚未被系统地描述,很容易漏诊和误诊。病例摘要:本文报告了三例 SCLC 胃转移病例。第一例患者主要表现为咳嗽、咯血和上腹饱胀。另外两名患者主要表现为腹部不适、上腹胀痛。所有患者都接受了胃镜和造影检查。同时,三名患者病灶的免疫组化结果均提示为小细胞癌。最后,通过综合分析,三名患者被确诊为 SCLC 胃转移。结论:在此,我们重点总结了SCLC胃转移的特点,以提高临床医生对该疾病的认识。
{"title":"Gastric metastasis of small cell lung carcinoma: Three case reports and review of literature.","authors":"Shan Yang, Qing-Yun He, Qing-Jing Zhao, Han-Tao Yang, Zheng-Yi Yang, Wen-Yi Che, Hua-Mei Li, Hui-Chao Wu","doi":"10.3748/wjg.v30.i31.3717","DOIUrl":"10.3748/wjg.v30.i31.3717","url":null,"abstract":"<p><strong>Background: </strong>Small cell lung carcinoma (SCLC) is highly susceptible to metastasis in the early stages of the disease. However, the stomach is an uncommon site of metastasis in SCLC, and only a few cases of this type of metastasis have been reported. Therefore, SCLC gastric metastases have not been systematically characterized and are easily missed and misdiagnosed.</p><p><strong>Case summary: </strong>We report three cases of gastric metastasis from SCLC in this article. The first patient presented primarily with cough, hemoptysis, and epigastric fullness. The other two patients presented primarily with abdominal discomfort, epigastric distension, and pain. All patients underwent gastroscopy and imaging examinations. Meanwhile, the immunohistochemical results of the lesions in three patients were suggestive of small cell carcinoma. Finally, the three patients were diagnosed with gastric metastasis of SCLC through a comprehensive analysis. The three patients did not receive appropriate treatment and died within a short time.</p><p><strong>Conclusion: </strong>Here, we focused on summarizing the characteristics of gastric metastasis of SCLC to enhance clinicians' understanding of this disease.</p>","PeriodicalId":23778,"journal":{"name":"World Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11346160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142081835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of spray flushing in the reprocessing of flexible endoscopes: A randomized controlled trial. 喷淋冲洗在重新处理柔性内窥镜中的功效:随机对照试验。
IF 4.3 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-21 DOI: 10.3748/wjg.v30.i31.3680
Jiang Du, Miao Zhang, Si-Yuan Tao, Lian-Song Ye, Hui Gong, Bing Hu, Qiong-Ying Zhang, Fu Qiao

Background: Commonly used cleaning brushes in the reprocessing of flexible endoscopes often cause damage within the working channels.

Aim: To develop a spray flushing system to achieving effective cleaning of the working channels while minimizing damage.

Methods: This prospective study included 60 used endoscopes and 60 Teflon tubes randomly divided into a control group (n = 30) and an experimental group (n = 30). The material of Teflon tubes was the same as that of the endoscope working channel. Endoscopes in the control group were manually cleaned using traditional cleaning brushes, while those in the experimental group were cleaned using the newly developed spray flushing system. ATP levels, cleanliness, and microbiological testing of the working channels were measured. Additionally, Teflon tubes in the control group underwent 500 passes with a cleaning brush, while those in the experimental group were subjected to the spray flushing system, and channel damage was evaluated.

Results: The ATP levels (RLU) in the two groups were 32.5 (13-66) and 26 (16-40), respectively (P > 0.05). Cleanliness scores were 1.5 (1-2) and 1 (1-2), respectively (P > 0.05). Debris was found in 73.3% of the control group, which was significantly higher than 46.7% in the experimental group (P < 0.05). Microbiological tests for both groups yielded negative results. Teflon tube damage in the control group was rated at 4 (4-5.25), which was significantly higher than in the experimental group 4 (3-4) (P < 0.01).

Conclusion: The spray flushing system demonstrated superior efficacy in removing debris and resulted in less damage to the endoscope working channels compared with traditional cleaning brushes.

背景:目的:开发一种喷淋冲洗系统,在有效清洗工作通道的同时最大限度地减少损伤:这项前瞻性研究包括 60 个使用过的内窥镜和 60 个特氟龙管,随机分为对照组(n = 30)和实验组(n = 30)。特氟龙管的材料与内窥镜工作通道的材料相同。对照组的内窥镜使用传统的清洁刷进行人工清洁,而实验组的内窥镜则使用新开发的喷淋冲洗系统进行清洁。对工作通道的 ATP 水平、清洁度和微生物检测进行了测量。此外,对照组的聚四氟乙烯管用清洁刷清洗了 500 次,而实验组的聚四氟乙烯管则使用了喷淋冲洗系统,并对通道损坏情况进行了评估:两组的 ATP 水平(RLU)分别为 32.5(13-66)和 26(16-40)(P > 0.05)。清洁度评分分别为 1.5(1-2)和 1(1-2)(P > 0.05)。对照组中有 73.3% 发现了杂物,明显高于实验组的 46.7%(P < 0.05)。两组的微生物检测结果均为阴性。对照组特氟龙管损坏率为 4(4-5.25),明显高于实验组的 4(3-4)(P < 0.01):与传统的清洁刷相比,喷淋冲洗系统在清除碎屑方面表现出更高的功效,对内窥镜工作通道造成的损坏也更小。
{"title":"Efficacy of spray flushing in the reprocessing of flexible endoscopes: A randomized controlled trial.","authors":"Jiang Du, Miao Zhang, Si-Yuan Tao, Lian-Song Ye, Hui Gong, Bing Hu, Qiong-Ying Zhang, Fu Qiao","doi":"10.3748/wjg.v30.i31.3680","DOIUrl":"10.3748/wjg.v30.i31.3680","url":null,"abstract":"<p><strong>Background: </strong>Commonly used cleaning brushes in the reprocessing of flexible endoscopes often cause damage within the working channels.</p><p><strong>Aim: </strong>To develop a spray flushing system to achieving effective cleaning of the working channels while minimizing damage.</p><p><strong>Methods: </strong>This prospective study included 60 used endoscopes and 60 Teflon tubes randomly divided into a control group (<i>n</i> = 30) and an experimental group (<i>n</i> = 30). The material of Teflon tubes was the same as that of the endoscope working channel. Endoscopes in the control group were manually cleaned using traditional cleaning brushes, while those in the experimental group were cleaned using the newly developed spray flushing system. ATP levels, cleanliness, and microbiological testing of the working channels were measured. Additionally, Teflon tubes in the control group underwent 500 passes with a cleaning brush, while those in the experimental group were subjected to the spray flushing system, and channel damage was evaluated.</p><p><strong>Results: </strong>The ATP levels (RLU) in the two groups were 32.5 (13-66) and 26 (16-40), respectively (<i>P</i> > 0.05). Cleanliness scores were 1.5 (1-2) and 1 (1-2), respectively (<i>P</i> > 0.05). Debris was found in 73.3% of the control group, which was significantly higher than 46.7% in the experimental group (<i>P</i> < 0.05). Microbiological tests for both groups yielded negative results. Teflon tube damage in the control group was rated at 4 (4-5.25), which was significantly higher than in the experimental group 4 (3-4) (<i>P</i> < 0.01).</p><p><strong>Conclusion: </strong>The spray flushing system demonstrated superior efficacy in removing debris and resulted in less damage to the endoscope working channels compared with traditional cleaning brushes.</p>","PeriodicalId":23778,"journal":{"name":"World Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11346163/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142081834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unveiling the anticancer effect of traditional Chinese herbal medicine. 揭示传统中草药的抗癌作用。
IF 4.3 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-14 DOI: 10.3748/wjg.v30.i30.3625
Naoki Asano

In this issue of World Journal of Gastroenterology, Huang et al reported that Calculus bovis (CB), a traditional Chinese herbal medicine, impedes the growth of liver cancers in vivo. Through further in vitro studies, they showed that CB suppressed the M2 polarization of tumor-associated macrophages by suppressing the Wnt signaling pathway, which consequently inhibited the growth of liver cancer. Although the effects of traditional Chinese herbal medicine are often not scientifically proven, Huang et al successfully identified the molecular mechanism involved in the anticancer effect of CB, and it is anticipated that the molecular mechanisms involved in the effects of other traditional Chinese herbal medicines will be scientifically elucidated, as demonstrated in this article.

在本期《世界胃肠病学杂志》(World Journal of Gastroenterology)上,Huang 等人报道了传统中药牛黄(CB)能在体内阻碍肝癌的生长。通过进一步的体外研究,他们发现牛黄通过抑制 Wnt 信号通路,抑制了肿瘤相关巨噬细胞的 M2 极化,从而抑制了肝癌的生长。虽然传统中草药的作用往往没有科学依据,但Huang等人成功鉴定了CB抗癌作用的分子机制,预计其他传统中草药的作用分子机制也将如本文所示得到科学阐明。
{"title":"Unveiling the anticancer effect of traditional Chinese herbal medicine.","authors":"Naoki Asano","doi":"10.3748/wjg.v30.i30.3625","DOIUrl":"10.3748/wjg.v30.i30.3625","url":null,"abstract":"<p><p>In this issue of <i>World Journal of Gastroenterology</i>, Huang <i>et al</i> reported that Calculus bovis (CB), a traditional Chinese herbal medicine, impedes the growth of liver cancers <i>in vivo</i>. Through further <i>in vitro</i> studies, they showed that CB suppressed the M2 polarization of tumor-associated macrophages by suppressing the Wnt signaling pathway, which consequently inhibited the growth of liver cancer. Although the effects of traditional Chinese herbal medicine are often not scientifically proven, Huang <i>et al</i> successfully identified the molecular mechanism involved in the anticancer effect of CB, and it is anticipated that the molecular mechanisms involved in the effects of other traditional Chinese herbal medicines will be scientifically elucidated, as demonstrated in this article.</p>","PeriodicalId":23778,"journal":{"name":"World Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11346149/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142081830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease. 胰高血糖素样肽 1 激动剂是治疗代谢功能障碍相关性脂肪肝的潜在药物。
IF 4.3 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-14 DOI: 10.3748/wjg.v30.i30.3541
Maurizio Soresi, Lydia Giannitrapani

In this editorial, we comment on Yin et al's recently published Letter to the editor. In particular, we focus on the potential use of glucagon-like peptide 1 receptor agonists (GLP-1RAs) alone, but even more so in combination therapy, as one of the most promising therapies in metabolic dysfunction-associated steatotic liver disease (MASLD), the new definition of an old condition, non-alcoholic fatty liver disease, which aims to better define the spectrum of steatotic pathology. It is well known that GLP-1RAs, having shown outstanding performance in fat loss, weight loss, and improvement of insulin resistance, could play a role in protecting the liver from progressive damage. Several clinical trials have shown that, among GLP-1RAs, semaglutide is a safe, well-studied therapeutic choice for MASLD patients; however, most studies demonstrate that, while semaglutide can reduce steatosis, including steatohepatitis histological signs (in terms of inflammatory cell infiltration and hepatocyte ballooning), it does not improve fibrosis. Combinations of therapies with different but complementary mechanisms of action are considered the best way to improve efficiency and slow disease progression due to the complex pathophysiology of the disease. In particular, GLP-1RAs associated with antifibrotic drug therapy, dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RA or GLP-1 and glucagon RAs have promoted greater improvement in hepatic steatosis, liver biochemistry, and non-invasive fibrosis tests than monotherapy. Therefore, although to date there are no definitive indications from international drug agencies, there is the hope that soon the therapeutic lines in the most advanced phase of study will be able to provide a therapy for MASLD, one that will certainly include the use of GLP-1RAs as combination therapy.

在这篇社论中,我们对 Yin 等人最近发表的致编辑的信进行了评论。我们特别关注胰高血糖素样肽 1 受体激动剂(GLP-1RA)单独使用,甚至联合使用的潜力,将其作为代谢功能障碍相关性脂肪肝(MASLD)最有前景的疗法之一。MASLD 是对非酒精性脂肪肝这一老病症的新定义,旨在更好地界定脂肪肝的病理范围。众所周知,GLP-1RAs 在减脂、减肥和改善胰岛素抵抗方面表现突出,可在保护肝脏免受进行性损伤方面发挥作用。多项临床试验表明,在 GLP-1RAs 中,对于 MASLD 患者来说,塞马鲁肽是一种安全的、经过充分研究的治疗选择;然而,大多数研究表明,虽然塞马鲁肽可以减轻脂肪变性,包括脂肪性肝炎组织学征象(炎症细胞浸润和肝细胞气球化),但并不能改善纤维化。由于该病的病理生理学非常复杂,因此将作用机制不同但互补的疗法组合在一起被认为是提高疗效和延缓疾病进展的最佳方法。与单一疗法相比,与抗纤维化药物疗法、葡萄糖依赖性胰岛素多肽(GIP)/GLP-1RA 双联疗法或 GLP-1 和胰高血糖素 RAs 联用的 GLP-1RA 可促进肝脏脂肪变性、肝脏生化和非侵入性纤维化测试的改善。因此,尽管迄今为止国际药品机构还没有明确的指示,但人们希望处于最后期研究阶段的治疗方案很快就能为 MASLD 提供一种疗法,其中肯定包括使用 GLP-1RA 作为联合疗法。
{"title":"Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease.","authors":"Maurizio Soresi, Lydia Giannitrapani","doi":"10.3748/wjg.v30.i30.3541","DOIUrl":"10.3748/wjg.v30.i30.3541","url":null,"abstract":"<p><p>In this editorial, we comment on Yin <i>et al</i>'s recently published Letter to the editor. In particular, we focus on the potential use of glucagon-like peptide 1 receptor agonists (GLP-1RAs) alone, but even more so in combination therapy, as one of the most promising therapies in metabolic dysfunction-associated steatotic liver disease (MASLD), the new definition of an old condition, non-alcoholic fatty liver disease, which aims to better define the spectrum of steatotic pathology. It is well known that GLP-1RAs, having shown outstanding performance in fat loss, weight loss, and improvement of insulin resistance, could play a role in protecting the liver from progressive damage. Several clinical trials have shown that, among GLP-1RAs, semaglutide is a safe, well-studied therapeutic choice for MASLD patients; however, most studies demonstrate that, while semaglutide can reduce steatosis, including steatohepatitis histological signs (in terms of inflammatory cell infiltration and hepatocyte ballooning), it does not improve fibrosis. Combinations of therapies with different but complementary mechanisms of action are considered the best way to improve efficiency and slow disease progression due to the complex pathophysiology of the disease. In particular, GLP-1RAs associated with antifibrotic drug therapy, dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RA or GLP-1 and glucagon RAs have promoted greater improvement in hepatic steatosis, liver biochemistry, and non-invasive fibrosis tests than monotherapy. Therefore, although to date there are no definitive indications from international drug agencies, there is the hope that soon the therapeutic lines in the most advanced phase of study will be able to provide a therapy for MASLD, one that will certainly include the use of GLP-1RAs as combination therapy.</p>","PeriodicalId":23778,"journal":{"name":"World Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11346152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142081826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fanlian Huazhuo Formula alleviates high-fat diet-induced non-alcoholic fatty liver disease by modulating autophagy and lipid synthesis signaling pathway. 黄连化脂方通过调节自噬和脂质合成信号通路缓解高脂饮食诱导的非酒精性脂肪肝
IF 4.3 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-14 DOI: 10.3748/wjg.v30.i30.3584
Meng-Yuan Niu, Geng-Ting Dong, Yi Li, Qing Luo, Liu Cao, Xi-Min Wang, Qi-Wen Wang, Yi-Ting Wang, Zhe Zhang, Xi-Wen Zhong, Wei-Bo Dai, Le-Yu Li

Background: Fanlian Huazhuo Formula (FLHZF) has the functions of invigorating spleen and resolving phlegm, clearing heat and purging turbidity. It has been identified to have therapeutic effects on type 2 diabetes mellitus (T2DM) in clinical application. Non-alcoholic fatty liver disease (NAFLD) is frequently diagnosed in patients with T2DM. However, the therapeutic potential of FLHZF on NAFLD and the underlying mechanisms need further investigation.

Aim: To elucidate the effects of FLHZF on NAFLD and explore the underlying hepatoprotective mechanisms in vivo and in vitro.

Methods: HepG2 cells were treated with free fatty acid for 24 hours to induce lipid accumulation cell model. Subsequently, experiments were conducted with the different concentrations of freeze-dried powder of FLHZF for 24 hours. C57BL/6 mice were fed a high-fat diet for 8-week to establish a mouse model of NAFLD, and then treated with the different concentrations of FLHZF for 10 weeks.

Results: FLHZF had therapeutic potential against lipid accumulation and abnormal changes in biochemical indicators in vivo and in vitro. Further experiments verified that FLHZF alleviated abnormal lipid metabolism might by reducing oxidative stress, regulating the AMPKα/SREBP-1C signaling pathway, activating autophagy, and inhibiting hepatocyte apoptosis.

Conclusion: FLHZF alleviates abnormal lipid metabolism in NAFLD models by regulating reactive oxygen species, autophagy, apoptosis, and lipid synthesis signaling pathways, indicating its potential for clinical application in NAFLD.

背景介绍粉莲化浊方具有健脾化痰、清热涤浊的作用。在临床应用中发现,它对 2 型糖尿病(T2DM)有治疗作用。非酒精性脂肪肝(NAFLD)是 T2DM 患者的常见病。方法:用游离脂肪酸处理 HepG2 细胞 24 小时,诱导脂质蓄积细胞模型。方法:用游离脂肪酸处理 HepG2 细胞 24 小时,诱导脂质蓄积细胞模型,然后用不同浓度的 FLHZF 冻干粉进行 24 小时实验。对C57BL/6小鼠进行为期8周的高脂饮食以建立非酒精性脂肪肝小鼠模型,然后用不同浓度的FLHZF治疗10周:结果:FLHZF对非酒精性脂肪肝小鼠体内和体外的脂质蓄积和生化指标异常变化具有治疗潜力。进一步的实验证实,FLHZF可通过降低氧化应激、调节AMPKα/SREBP-1C信号通路、激活自噬和抑制肝细胞凋亡来缓解脂质代谢异常:结论:FLHZF可通过调节活性氧、自噬、细胞凋亡和脂质合成信号通路,缓解非酒精性脂肪肝模型中的脂质代谢异常,表明其在非酒精性脂肪肝中的临床应用潜力。
{"title":"Fanlian Huazhuo Formula alleviates high-fat diet-induced non-alcoholic fatty liver disease by modulating autophagy and lipid synthesis signaling pathway.","authors":"Meng-Yuan Niu, Geng-Ting Dong, Yi Li, Qing Luo, Liu Cao, Xi-Min Wang, Qi-Wen Wang, Yi-Ting Wang, Zhe Zhang, Xi-Wen Zhong, Wei-Bo Dai, Le-Yu Li","doi":"10.3748/wjg.v30.i30.3584","DOIUrl":"10.3748/wjg.v30.i30.3584","url":null,"abstract":"<p><strong>Background: </strong>Fanlian Huazhuo Formula (FLHZF) has the functions of invigorating spleen and resolving phlegm, clearing heat and purging turbidity. It has been identified to have therapeutic effects on type 2 diabetes mellitus (T2DM) in clinical application. Non-alcoholic fatty liver disease (NAFLD) is frequently diagnosed in patients with T2DM. However, the therapeutic potential of FLHZF on NAFLD and the underlying mechanisms need further investigation.</p><p><strong>Aim: </strong>To elucidate the effects of FLHZF on NAFLD and explore the underlying hepatoprotective mechanisms <i>in vivo</i> and <i>in vitro</i>.</p><p><strong>Methods: </strong>HepG2 cells were treated with free fatty acid for 24 hours to induce lipid accumulation cell model. Subsequently, experiments were conducted with the different concentrations of freeze-dried powder of FLHZF for 24 hours. <i>C57BL/6</i> mice were fed a high-fat diet for 8-week to establish a mouse model of NAFLD, and then treated with the different concentrations of FLHZF for 10 weeks.</p><p><strong>Results: </strong>FLHZF had therapeutic potential against lipid accumulation and abnormal changes in biochemical indicators <i>in vivo</i> and <i>in vitro</i>. Further experiments verified that FLHZF alleviated abnormal lipid metabolism might by reducing oxidative stress, regulating the AMPKα/SREBP-1C signaling pathway, activating autophagy, and inhibiting hepatocyte apoptosis.</p><p><strong>Conclusion: </strong>FLHZF alleviates abnormal lipid metabolism in NAFLD models by regulating reactive oxygen species, autophagy, apoptosis, and lipid synthesis signaling pathways, indicating its potential for clinical application in NAFLD.</p>","PeriodicalId":23778,"journal":{"name":"World Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11346146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142081867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recommendations for articles and reviews in colorectal cancer-related research at the year-end of 2023. 关于 2023 年底结直肠癌相关研究文章和评论的建议。
IF 4.3 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-14 DOI: 10.3748/wjg.v30.i30.3548
Wen-Yu Luan, Hao Lin, Yan-Dong Miao

As peer reviewers of the World Journal of Gastroenterology, our weekly routine involves immersing ourselves in the newly published issue, particularly focusing on the realm of colorectal cancer (CRC) research. We diligently sift through various contributions, ranging from comprehensive reviews to original articles and other scholarly works. Through meticulous examination, we discern the most notable papers, delving into each with careful scrutiny to distill their merits and shortcomings. Undoubtedly, this undertaking demands considerable time and effort. Yet, it stands as an indispensable pursuit, affording us a profound comprehension of the latest breakthroughs in CRC research. Moreover, these meticulously curated selections furnish readers with invaluable resources, serving as enduring references for the nuanced exploration of this dynamic field.

作为《世界胃肠病学杂志》的同行评审员,我们每周的例行工作包括沉浸在新出版的期刊中,尤其是关注结直肠癌 (CRC) 研究领域。我们认真筛选各种稿件,包括综合评论、原创文章和其他学术著作。通过细致入微的检查,我们找出了最值得关注的论文,对每篇论文都进行了仔细的研究,以提炼出它们的优点和不足。毫无疑问,这项工作需要花费大量的时间和精力。然而,这是一项不可或缺的工作,它让我们深刻理解了 CRC 研究的最新突破。此外,这些经过精心策划的选集还为读者提供了宝贵的资源,可作为对这一充满活力的领域进行细致探索的持久参考。
{"title":"Recommendations for articles and reviews in colorectal cancer-related research at the year-end of 2023.","authors":"Wen-Yu Luan, Hao Lin, Yan-Dong Miao","doi":"10.3748/wjg.v30.i30.3548","DOIUrl":"10.3748/wjg.v30.i30.3548","url":null,"abstract":"<p><p>As peer reviewers of the <i>World Journal of Gastroenterology</i>, our weekly routine involves immersing ourselves in the newly published issue, particularly focusing on the realm of colorectal cancer (CRC) research. We diligently sift through various contributions, ranging from comprehensive reviews to original articles and other scholarly works. Through meticulous examination, we discern the most notable papers, delving into each with careful scrutiny to distill their merits and shortcomings. Undoubtedly, this undertaking demands considerable time and effort. Yet, it stands as an indispensable pursuit, affording us a profound comprehension of the latest breakthroughs in CRC research. Moreover, these meticulously curated selections furnish readers with invaluable resources, serving as enduring references for the nuanced exploration of this dynamic field.</p>","PeriodicalId":23778,"journal":{"name":"World Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11346154/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142081829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Link between childhood obesity and gut microbiota. 儿童肥胖与肠道微生物群之间的联系。
IF 4.3 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-14 DOI: 10.3748/wjg.v30.i30.3560
Yan Pan, Fu-Yong Jiao

Childhood obesity is a critical global health concern with rising prevalence and significant long-term health implications. Recent studies have implicated gut microbiota in the development and progression of obesity. This editorial analyzes the research conducted by Li et al, who utilized 16S rRNA gene sequencing to compare the gut microbiome of overweight and healthy-weight children. The study found significant differences in microbial diversity and composition between the two groups, with potential implications for understanding and managing childhood obesity. We analyzed the study's advantages and drawbacks, proposing potential areas for future research to better understand the connection between gut microbiota and obesity.

儿童肥胖症是一个严重的全球健康问题,发病率不断上升,对健康产生了重大的长期影响。最近的研究表明,肠道微生物群与肥胖症的发生和发展有关。这篇社论分析了 Li 等人的研究,他们利用 16S rRNA 基因测序比较了超重儿童和健康体重儿童的肠道微生物群。研究发现,两组儿童的微生物多样性和组成存在明显差异,这对了解和管理儿童肥胖症具有潜在的意义。我们分析了这项研究的优点和缺点,提出了未来研究的潜在领域,以便更好地了解肠道微生物群与肥胖之间的联系。
{"title":"Link between childhood obesity and gut microbiota.","authors":"Yan Pan, Fu-Yong Jiao","doi":"10.3748/wjg.v30.i30.3560","DOIUrl":"10.3748/wjg.v30.i30.3560","url":null,"abstract":"<p><p>Childhood obesity is a critical global health concern with rising prevalence and significant long-term health implications. Recent studies have implicated gut microbiota in the development and progression of obesity. This editorial analyzes the research conducted by Li <i>et al</i>, who utilized 16S rRNA gene sequencing to compare the gut microbiome of overweight and healthy-weight children. The study found significant differences in microbial diversity and composition between the two groups, with potential implications for understanding and managing childhood obesity. We analyzed the study's advantages and drawbacks, proposing potential areas for future research to better understand the connection between gut microbiota and obesity.</p>","PeriodicalId":23778,"journal":{"name":"World Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11346147/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142081827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Parasites of the liver: A global problem? 肝脏寄生虫:全球性问题?
IF 4.3 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-14 DOI: 10.3748/wjg.v30.i30.3554
Vladislav V Tsukanov, Alexander V Vasyutin, Julia L Tonkikh

Parasitic liver diseases can be caused by trematodes, cestodes, nematodes, and protozoa. This pathology is significant because millions of people in different parts of the world have liver parasites, which can manifest themselves in the development of inflammation, liver cysts, cholecystitis, cholelithiasis, pancreatitis and liver cirrhosis that are often threatening their lives. The International Agency for Research on Cancer considers three species of trematodes, Schistosoma haematobium, Opisthorchis viverrini and Clonorchis sinensis, to be carcinogens. Complex modern examination methods, in some cases including extensive screening of large populations, are required for diagnosing liver parasites. Treatment of parasitic liver diseases is differentiated and can involve a combination of surgical and therapeutic measures. There is no doubt that the clinical and epidemiological scale allows one to regard parasitic liver diseases as a global healthcare problem.

寄生虫肝病可由吸虫、绦虫、线虫和原虫引起。这种病理变化意义重大,因为世界各地有数百万人患有肝寄生虫病,其表现形式包括发生炎症、肝囊肿、胆囊炎、胆石症、胰腺炎和肝硬化,这些疾病往往威胁着他们的生命。国际癌症研究机构认为三种吸虫,即血吸虫(Schistosoma haematobium)、疟原虫(Opisthorchis viverrini)和中华疟原虫(Clonorchis sinensis)是致癌物质。诊断肝脏寄生虫需要复杂的现代检查方法,在某些情况下包括对大量人群进行广泛筛查。寄生虫肝病的治疗是有区别的,可能涉及手术和治疗措施的结合。毫无疑问,从临床和流行病学的角度来看,寄生虫性肝病是一个全球性的医疗保健问题。
{"title":"Parasites of the liver: A global problem?","authors":"Vladislav V Tsukanov, Alexander V Vasyutin, Julia L Tonkikh","doi":"10.3748/wjg.v30.i30.3554","DOIUrl":"10.3748/wjg.v30.i30.3554","url":null,"abstract":"<p><p>Parasitic liver diseases can be caused by trematodes, cestodes, nematodes, and protozoa. This pathology is significant because millions of people in different parts of the world have liver parasites, which can manifest themselves in the development of inflammation, liver cysts, cholecystitis, cholelithiasis, pancreatitis and liver cirrhosis that are often threatening their lives. The International Agency for Research on Cancer considers three species of trematodes, <i>Schistosoma haematobium</i>, <i>Opisthorchis viverrini</i> and <i>Clonorchis sinensis</i>, to be carcinogens. Complex modern examination methods, in some cases including extensive screening of large populations, are required for diagnosing liver parasites. Treatment of parasitic liver diseases is differentiated and can involve a combination of surgical and therapeutic measures. There is no doubt that the clinical and epidemiological scale allows one to regard parasitic liver diseases as a global healthcare problem.</p>","PeriodicalId":23778,"journal":{"name":"World Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11346153/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142078293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers: An open-label, non-randomized, phase II clinical trial. 纳布-紫杉醇加卡培他滨作为晚期胆道癌的一线治疗:一项开放标签、非随机II期临床试验。
IF 4.3 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-14 DOI: 10.3748/wjg.v30.i30.3564
Ling-Xiao Xu, Jia-Jia Yuan, Ran Xue, Jun Zhou

Background: Biliary tract cancers (BTCs) are a heterogeneous group of tumors with high malignancy, poor prognosis, and limited treatment options.

Aim: To explore the efficacy and safety of nab-paclitaxel plus capecitabine as first-line treatment for advanced and metastatic BTCs.

Methods: This open-label, non-randomized, double-center, phase II clinical trial recruited systemic therapy-naive patients with unresectable or metastatic BTCs between April 2019 and June 2022 at Beijing Cancer Hospital and the First Hospital of China Medical University. Eligible patients were administered nab-paclitaxel (150 mg/m2, day 1) and capecitabine (2000 mg/m2, twice daily, days 1-7) in 14-day cycles until experiencing intolerable toxicity or disease progression. The primary outcome was the objective response rate (ORR). The secondary outcomes included the disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and safety.

Results: A total of 44 patients successfully completed the trial, with a median age of 64.00 years (interquartile range, 35.00-76.00), and 26 (59.09%) were females. Tumor response assessment was impeded for one patient due to premature demise from tumor hemorrhage. Among the remaining 43 patients undergoing at least one imaging assessment, the ORR was 23.26% [95% confidence interval (CI): 11.80%-38.60%], and the DCR was 69.77% (95%CI: 53.90%-82.80%). The median OS was 14.1 months (95%CI: 8.3-19.9), and the median PFS was 4.4 months (95%CI: 2.5-6.3). A total of 41 patients (93.18%) experienced at least one adverse event (AE), with 10 patients (22.73%) encountering grade ≥ 3 AEs, and the most frequent AEs of any grade were alopecia (79.50%), leukopenia (54.55%), neutropenia (52.27%), and liver dysfunction (40.91%), and no treatment-related deaths were documented.

Conclusion: Nab-paclitaxel plus capecitabine may be an effective and safe first-line treatment strategy for patients with advanced or metastatic BTCs.

背景:目的:探讨纳布-紫杉醇联合卡培他滨一线治疗晚期和转移性BTC的有效性和安全性:这项开放标签、非随机、双中心、II期临床试验招募了2019年4月至2022年6月期间在北京肿瘤医院和中国医科大学附属第一医院接受系统治疗的不可切除或转移性BTC患者。符合条件的患者接受纳布-紫杉醇(150 毫克/平方米,第 1 天)和卡培他滨(2000 毫克/平方米,每天两次,第 1-7 天)治疗,14 天为一个周期,直至出现不可耐受的毒性或疾病进展。主要结果是客观反应率(ORR)。次要结果包括疾病控制率(DCR)、总生存期(OS)、无进展生存期(PFS)和安全性:共有 44 名患者成功完成了试验,中位年龄为 64.00 岁(四分位数间距为 35.00-76.00),其中女性 26 人(59.09%)。一名患者因肿瘤出血过早死亡,导致肿瘤反应评估受阻。在其余43名接受过至少一次成像评估的患者中,ORR为23.26%[95%置信区间(CI):11.80%-38.60%],DCR为69.77%(95%CI:53.90%-82.80%)。中位 OS 为 14.1 个月(95%CI:8.3-19.9),中位 PFS 为 4.4 个月(95%CI:2.5-6.3)。共有41名患者(93.18%)发生了至少一次不良事件(AE),其中10名患者(22.73%)发生了≥3级的不良事件,最常见的任何级别的不良事件为脱发(79.50%)、白细胞减少(54.55%)、中性粒细胞减少(52.27%)和肝功能异常(40.91%),无治疗相关死亡记录:纳布-紫杉醇联合卡培他滨可能是晚期或转移性BTC患者有效且安全的一线治疗策略。
{"title":"Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers: An open-label, non-randomized, phase II clinical trial.","authors":"Ling-Xiao Xu, Jia-Jia Yuan, Ran Xue, Jun Zhou","doi":"10.3748/wjg.v30.i30.3564","DOIUrl":"10.3748/wjg.v30.i30.3564","url":null,"abstract":"<p><strong>Background: </strong>Biliary tract cancers (BTCs) are a heterogeneous group of tumors with high malignancy, poor prognosis, and limited treatment options.</p><p><strong>Aim: </strong>To explore the efficacy and safety of nab-paclitaxel plus capecitabine as first-line treatment for advanced and metastatic BTCs.</p><p><strong>Methods: </strong>This open-label, non-randomized, double-center, phase II clinical trial recruited systemic therapy-naive patients with unresectable or metastatic BTCs between April 2019 and June 2022 at Beijing Cancer Hospital and the First Hospital of China Medical University. Eligible patients were administered nab-paclitaxel (150 mg/m<sup>2</sup>, day 1) and capecitabine (2000 mg/m<sup>2</sup>, twice daily, days 1-7) in 14-day cycles until experiencing intolerable toxicity or disease progression. The primary outcome was the objective response rate (ORR). The secondary outcomes included the disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and safety.</p><p><strong>Results: </strong>A total of 44 patients successfully completed the trial, with a median age of 64.00 years (interquartile range, 35.00-76.00), and 26 (59.09%) were females. Tumor response assessment was impeded for one patient due to premature demise from tumor hemorrhage. Among the remaining 43 patients undergoing at least one imaging assessment, the ORR was 23.26% [95% confidence interval (CI): 11.80%-38.60%], and the DCR was 69.77% (95%CI: 53.90%-82.80%). The median OS was 14.1 months (95%CI: 8.3-19.9), and the median PFS was 4.4 months (95%CI: 2.5-6.3). A total of 41 patients (93.18%) experienced at least one adverse event (AE), with 10 patients (22.73%) encountering grade ≥ 3 AEs, and the most frequent AEs of any grade were alopecia (79.50%), leukopenia (54.55%), neutropenia (52.27%), and liver dysfunction (40.91%), and no treatment-related deaths were documented.</p><p><strong>Conclusion: </strong>Nab-paclitaxel plus capecitabine may be an effective and safe first-line treatment strategy for patients with advanced or metastatic BTCs.</p>","PeriodicalId":23778,"journal":{"name":"World Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11346148/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142081828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical application of eight-zone laparoscopic dissection strategy for rectal cancer: Experience and discussion. 直肠癌八区腹腔镜解剖策略的临床应用:经验与讨论。
IF 4.3 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-14 DOI: 10.3748/wjg.v30.i30.3574
Chang Chen, Xiang Zhang, Xin Li, Yan-Lei Wang

Background: The incidence of rectal cancer is increasing worldwide, and surgery remains the primary treatment modality. With the advent of total mesorectal excision (TME) technique, the probability of tumor recurrence post-surgery has significantly decreased. Surgeons' focus has gradually shifted towards minimizing the impact of surgery on urinary and sexual functions. Among these concerns, the optimal dissection of the rectal lateral ligaments and preservation of the pelvic floor neurovascular bundle have become critical. To explore the optimal surgical technique for TME and establish a standardized surgical protocol to minimize the impact on urinary and sexual functions, we propose the eight-zone dissection strategy for pelvic floor anatomy.

Aim: To compare the differences in surgical specimen integrity and postoperative quality of life satisfaction between the traditional pelvic floor dissection strategy and the innovative eight-zone dissection strategy.

Methods: We analyzed the perioperative data of patients who underwent laparoscopic radical resection of rectal cancer at Qilu Hospital of Shandong University between January 1, 2021 and December 1, 2023. This study included a total of 218 patients undergoing laparoscopic radical surgery for rectal cancer, among whom 109 patients underwent traditional pelvic floor dissection strategy, and 109 patients received the eight-zone dissection strategy.

Results: There were no significant differences in general characteristics between the two groups. Patients in the eight-zone dissection group had higher postoperative specimen integrity (88.1% vs 78.0%, P = 0.047). At the 3-month follow-up, patients in the eight-zone surgery group had better scores in urinary issues (6.8 ± 3.3 vs 5.3 ± 2.5, P = 0.045) and male sexual desire (2.2 ± 0.6 vs 2.5 ± 0.5, P = 0.047) compared to the traditional surgery strategy group.

Conclusion: This study demonstrates that the eight-zone dissection strategy for laparoscopic lateral ligament dissection of rectal cancer is safe and effective. Compared with the traditional pelvic floor dissection strategy, this approach can reduce the risk of nerve injury and minimize the impact on urinary and sexual functions. Therefore, we recommend the clinical application of this strategy to better serve patients with rectal cancer.

背景:直肠癌的发病率在全球范围内不断上升,手术仍是主要的治疗方式。随着全直肠系膜切除术(TME)技术的出现,手术后肿瘤复发的概率大大降低。外科医生的工作重心逐渐转向尽量减少手术对泌尿和性功能的影响。其中,直肠侧韧带的最佳解剖和盆底神经血管束的保留已变得至关重要。目的:比较传统的盆底解剖策略和创新的八区解剖策略在手术标本完整性和术后生活质量满意度方面的差异:我们分析了2021年1月1日至2023年12月1日期间在山东大学齐鲁医院接受腹腔镜直肠癌根治性切除术的患者的围手术期数据。该研究共纳入218例接受腹腔镜直肠癌根治术的患者,其中109例患者接受了传统的盆底解剖策略,109例患者接受了八区解剖策略:结果:两组患者的一般特征无明显差异。八区解剖组患者的术后标本完整性更高(88.1% 对 78.0%,P = 0.047)。在3个月的随访中,八区手术组患者在排尿问题(6.8 ± 3.3 vs 5.3 ± 2.5,P = 0.045)和男性性欲(2.2 ± 0.6 vs 2.5 ± 0.5,P = 0.047)方面的评分优于传统手术策略组:本研究表明,腹腔镜直肠癌侧韧带切除术的八区切除策略安全有效。结论:本研究表明,腹腔镜下直肠癌侧韧带切除术的八区解剖策略是安全有效的,与传统的盆底解剖策略相比,这种方法可以降低神经损伤的风险,最大限度地减少对泌尿和性功能的影响。因此,我们建议临床应用这种策略,以便更好地为直肠癌患者服务。
{"title":"Clinical application of eight-zone laparoscopic dissection strategy for rectal cancer: Experience and discussion.","authors":"Chang Chen, Xiang Zhang, Xin Li, Yan-Lei Wang","doi":"10.3748/wjg.v30.i30.3574","DOIUrl":"10.3748/wjg.v30.i30.3574","url":null,"abstract":"<p><strong>Background: </strong>The incidence of rectal cancer is increasing worldwide, and surgery remains the primary treatment modality. With the advent of total mesorectal excision (TME) technique, the probability of tumor recurrence post-surgery has significantly decreased. Surgeons' focus has gradually shifted towards minimizing the impact of surgery on urinary and sexual functions. Among these concerns, the optimal dissection of the rectal lateral ligaments and preservation of the pelvic floor neurovascular bundle have become critical. To explore the optimal surgical technique for TME and establish a standardized surgical protocol to minimize the impact on urinary and sexual functions, we propose the eight-zone dissection strategy for pelvic floor anatomy.</p><p><strong>Aim: </strong>To compare the differences in surgical specimen integrity and postoperative quality of life satisfaction between the traditional pelvic floor dissection strategy and the innovative eight-zone dissection strategy.</p><p><strong>Methods: </strong>We analyzed the perioperative data of patients who underwent laparoscopic radical resection of rectal cancer at Qilu Hospital of Shandong University between January 1, 2021 and December 1, 2023. This study included a total of 218 patients undergoing laparoscopic radical surgery for rectal cancer, among whom 109 patients underwent traditional pelvic floor dissection strategy, and 109 patients received the eight-zone dissection strategy.</p><p><strong>Results: </strong>There were no significant differences in general characteristics between the two groups. Patients in the eight-zone dissection group had higher postoperative specimen integrity (88.1% <i>vs</i> 78.0%, <i>P</i> = 0.047). At the 3-month follow-up, patients in the eight-zone surgery group had better scores in urinary issues (6.8 ± 3.3 <i>vs</i> 5.3 ± 2.5, <i>P</i> = 0.045) and male sexual desire (2.2 ± 0.6 <i>vs</i> 2.5 ± 0.5, <i>P</i> = 0.047) compared to the traditional surgery strategy group.</p><p><strong>Conclusion: </strong>This study demonstrates that the eight-zone dissection strategy for laparoscopic lateral ligament dissection of rectal cancer is safe and effective. Compared with the traditional pelvic floor dissection strategy, this approach can reduce the risk of nerve injury and minimize the impact on urinary and sexual functions. Therefore, we recommend the clinical application of this strategy to better serve patients with rectal cancer.</p>","PeriodicalId":23778,"journal":{"name":"World Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11346151/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142081866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
World Journal of Gastroenterology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1